Cytokinetics Says US FDA Accepts New Drug Application for Aficamten to Treat Obstructive Hypertrophic Cardiomyopathy
Cytokinetics Says US FDA Accepts New Drug Application for Aficamten to Treat Obstructive Hypertrophic Cardiomyopathy
Cytokinetics宣布美国FDA已接受用于治疗阻塞性肥厚型心肌病的Aficamten新药申请
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册